Report finds PBMs are increasingly restricting patient access to medicines

More than 1,150 medicines were excluded from at least one of the three largest PBMs’ standard commercial formularies in 2022, according to a new report from Xcenda. The report is further evidence of...
Read More
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19

This week, PhRMA sponsored The Washington Post’s event, Coronavirus: Lessons of the Pandemic, where PhRMA president and CEO Stephen J. Ubl shared crucial lessons learned from the pandemic on how to...
Read More
The Centers for Medicare & Medicaid Services (CMS) recently released their National Health Expenditure (NHE) projections of health care spending in the United States through 2030. While these data...
Read More
What’s really happening when it comes to prescription drug costs

New data show how robust competition continues to keep national spending on life-saving medicines in check, even as new innovative treatments reach patients. According to the latest report by the...
Read More
New analysis confirms hospitals markup prices for oncology therapies

A recent study from The Journal of the American Medical Association (JAMA) examined 61 hospitals using data made public under new requirements from a recent price transparency regulation. The...
Read More
Analysis: States can help patients save nearly $1,000 annually on their medicines

According to a new Ipsos/PhRMA poll, most Americans — 82% — agree that lowering out-of-pocket costs for health care should be a top priority for policymakers. A good place to start in lowering these...
Read More
How standardized plans can improve patients’ access to medicines

While insurers negotiate steep discounts on medicines, they don’t always share these savings directly with patients. In recent years, insurers have shifted costs for brand medicines to patients by...
Read More
Correcting the record: Putting medicine costs and spending in context

Last week, the Senate Finance Committee held a hearing focused on drug prices where the discussion was filled with misleading claims. We agree too many Americans struggle to afford their medicines,...
Read More
Sharing rebates can save Americans with diabetes $500 each year and improve adherence, especially for Black and Hispanic Americans

A new study by GlobalData looked at brand oral antidiabetic drugs (OADs) and found that sharing negotiated rebates with patients in commercial health plans at the pharmacy counter can help lower...
Read More
Guest Post: If we truly want to cure complex diseases, politicians should reject price setting

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...
Read More